Potential biomarkers of Poly (ADP-ribose) polymerase inhibitors for cancer therapy

被引：0

作者：

Zhou, Haiyan ^{[1
,2
]}

Hu, Bailong ^{[3
]}

Li, Wei ^{[4
]}

Huang, Niwen ^{[5
]}

Wei, Bo ^{[4
]}

Mo, Xiangang ^{[4
]}

Zhang, Bei ^{[6
]}

Wang, Yiming ^{[7
]}

Liu, Xingde ^{[1
,4
]}

机构：

[1] Guizhou Med Univ, Guiyang 550004, Guizhou, Peoples R China

[2] Guizhou Med Univ, Affiliated Hosp, Clin Res Ctr, Guiyang 550004, Guizhou, Peoples R China

[3] Guizhou Med Univ, Affiliated Hosp, Dept Anesthesiol, Guiyang 550004, Guizhou, Peoples R China

[4] Guizhou Med Univ, Affiliated Hosp, Dept Cardiol, Guiyang 550004, Guizhou, Peoples R China

[5] Guizhou Med Univ Hosp, Dept Resp Med, Guiyang 550004, Guizhou, Peoples R China

[6] Guizhou Med Univ Hosp, Dept Ultrasound, Guiyang 550004, Guizhou, Peoples R China

[7] Guizhou Med Univ Hosp, Dept Psychiat, Guiyang 550004, Guizhou, Peoples R China

来源：

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE | 2018年 / 11卷 / 05期

基金：

中国国家自然科学基金;

关键词：

PARP; BRCA; biomarker; NEGATIVE BREAST-CANCER; PARP INHIBITOR; POLY(ADP-RIBOSE) POLYMERASE; HOMOLOGOUS RECOMBINATION; OVARIAN-CANCER; DOSE-ESCALATION; MUTANT-CELLS; SOLID TUMORS; IN-VITRO; PHASE-I;

D O I：

暂无

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

As Olaparib has received FDA-approval for treatment of cancer patients with BRCA1 and BRCA2 mutations, the target related on Poly (ADP-ribose) polymerase (PARP) inhibitors have been emerging as a novel therapy for treatment of patients with advanced ovarian cancer. It has been observed that PARP inhibitors have optimistic antitumor activity of patients in advanced ovarian cancer bearing homologous recombination (HR) defects, supporting a substantially wider role for PARPi. Strategies to identify other potential biomarkers remain under investigation. Herein, we review recent updates on potential moleculars to predict biomarker of PARPi for cancer therapy and proposed an integrated biomarker system to predict the "appropriate users" of PARPi. It may help overcome PARPi treatment failure, which reveal novel insights into clinical use of PARPi.

引用

下载

页码：4446 / 4453

页数：8

共 50 条

[1] Poly(ADP-ribose) polymerase inhibitors as cancer therapy
Hilton, John F.
Hadfield, Matthew J.
Tran, Minh-Thu
Shapiro, Geoffrey I.
FRONTIERS IN BIOSCIENCE-LANDMARK, 2013, 18 : 1393 - 1407
[2] The therapeutic potential of poly(ADP-ribose) polymerase inhibitors
Virág, L
Szabó, C
PHARMACOLOGICAL REVIEWS, 2002, 54 (03) : 375 - 429
[3] Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy
Singh, Bijay
Yang, Shicheng
Krishna, Apurva
Sridhar, Srinivas
FRONTIERS IN CHEMISTRY, 2020, 8
[4] Poly(ADP-Ribose) Polymerase Inhibitors
Garon, Edward B.
Dubnett, Steven M.
JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S455 - S456
[5] Poly(ADP-ribose) polymerase inhibitors
Southan, GJ
Szabó, C
CURRENT MEDICINAL CHEMISTRY, 2003, 10 (04) : 321 - 340
[6] Poly (ADP-ribose) Polymerase Inhibitors in Cancer Treatment
Mason, Kathryn A.
Raju, Uma
Buchholz, Thomas A.
Wang, Li
Milas, Zvonimir L.
Milas, Luka
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2014, 37 (01): : 90 - 100
[7] The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer
Drew, Yvette
Plummer, Ruth
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2010, 22 (01) : 67 - 71
[8] Poly(ADP-ribose) polymerase inhibitors as potential chemotherapeutic agents
Bryant, HE
Helleday, T
BIOCHEMICAL SOCIETY TRANSACTIONS, 2004, 32 : 959 - 961
[9] Clinical Trials of Poly(ADP-Ribose) Polymerase Inhibitors for Cancer Therapy: A Review
Buege, Michael
Mahajan, Pramod B.
REVIEWS ON RECENT CLINICAL TRIALS, 2015, 10 (04) : 326 - 339
[10] Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy
Jannetti, Stephen A.
Zeglis, Brian M.
Zalutsky, Michael R.
Reiner, Thomas
FRONTIERS IN PHARMACOLOGY, 2020, 11

← 1 2 3 4 5 →